These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 11327441

  • 1. A pilot study of a combination of three reverse transcriptase inhibitors in HIV-1 infection.
    Lafeuillade A, Poggi C, Djediouane A, Chollet L, Profizi N, Sayada C.
    Antivir Ther; 1997 Dec; 2(4):219-27. PubMed ID: 11327441
    [Abstract] [Full Text] [Related]

  • 2. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J.
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [Abstract] [Full Text] [Related]

  • 3. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L, Cargnel A, Soranzo ML, Chirianni A, Ferraro T, Di Stefano M, Angarano G.
    Antivir Ther; 1999 Jul; 4(4):195-202. PubMed ID: 10723498
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C, Bellissant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, Bazin C, Renard I, Sébille V, Chauvin JP, Dohin E, Cartier F.
    Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
    [Abstract] [Full Text] [Related]

  • 5. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
    Clotet B, Ruiz L, Cabrera C, Ibáñez A, Cañadas MP, Sirera G, Romeu J, Vila J.
    Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
    [Abstract] [Full Text] [Related]

  • 6. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L, Romeu J, Ibáñez A, Cabrera C, Puig T, Morales MA, Sirera G, Clotet B.
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [Abstract] [Full Text] [Related]

  • 7. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A, Peraire J, Arnó A, Gutiérrez C, Cervantes M, Colomer J, Villalonga C, Camafort M, Ruiz L, Balaguer M, Vidal F, Richart C, Clotet B.
    Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, Agher R, Bricaire F, Costagliola D, Calvez V, Peytavin G, Katlama C.
    Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
    [Abstract] [Full Text] [Related]

  • 9. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Dec; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 10. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 11. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Mar; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 12. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Mar; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 13. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J, Marchou B, Charreau I, Sauné K, Tangre P, Molina JM, Aboulker JP, Window (ANRS 106) Study Team.
    Antivir Ther; 2008 Mar; 13(4):537-45. PubMed ID: 18672532
    [Abstract] [Full Text] [Related]

  • 14. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.
    Rusconi S, De Pasquale MP, Milazzo L, Moscatelli G, Bulgheroni E, Citterio P, d'Arminio-Monforte A, Moroni M, Galli M.
    Antivir Ther; 1997 Jan; 2(1):39-46. PubMed ID: 11322265
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Jan; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN, Feinberg J, Goodrich J, Pilson RS, Siemon-Hryczyk P.
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K.
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [Abstract] [Full Text] [Related]

  • 18. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F, ANRS 109 VISTA Study Group.
    Antivir Ther; 2006 Aug; 11(7):889-99. PubMed ID: 17302251
    [Abstract] [Full Text] [Related]

  • 19. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
    Canestri A, Ghosn J, Wirden M, Marguet F, Ktorza N, Boubezari I, Dominguez S, Bossi P, Caumes E, Calvez V, Katlama C.
    Antivir Ther; 2006 Aug; 11(5):561-6. PubMed ID: 16964823
    [Abstract] [Full Text] [Related]

  • 20. Zidovudine plus didanosine in primary HIV-1 infection.
    Perrin L, Yerly S, Charvier A, Figueras G, Schockmel GA, Hirschel B.
    Antivir Ther; 1997 Jan; 2(1):5-11. PubMed ID: 11322267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.